CEL-SCI Corporation
CVM · AMEX
Market closed$1.17$0.020000 (+1.74%)After hours $1.26 · +7.69%
Key statistics
Previous close$1.15
Open$1.13
Day high$1.17
Day low$1.09
52-week high$13.48
52-week low$0.890000
Market cap8.04M
Volume453.98K
Average volume539.65K
P/E ratio-0.22
Forward P/E—
EPS-5.41
Dividend yield0.00%
Market context
Why it moved
CVM's stock edged higher amid modest buying interest, likely supported by positive sentiment following a regulatory appeal decision in favor of Ecopetrol's Brazilian subsidiary, with no major company-specific catalysts driving a more significant move.
What is happening
Recent company-specific developments and publisher coverage.
BioBuzz · July 16, 2026CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerGuruFocus · July 14, 2026CEL-SCI (CVM) Initiates Global Study for Multikine in Head and NBusiness Wire · July 13, 2026CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerInvesting.com · July 13, 2026CEL-SCI launches confirmatory study for head and neck cancer drugStock Titan · June 24, 2026CEL-SCI and Saudi Amarox seal Multikine pact at BIO 2026Business Wire · June 14, 2026CEL-SCI Corporation Announces Pricing of OfferingBusiness Wire · May 18, 2026CEL-SCI Reports Fiscal Second Quarter 2026 ResultsStock Titan · May 11, 2026Saudi bid to fast-track cancer immunotherapy with new CEL-SCI deal Mt Newswire · July 13, 2026CEL-SCI to Launch Confirmatory Study of Multikine Benzinga · July 13, 2026CEL-SCI To Launch Phase 3 Confirmatory Study Mt Newswire · June 16, 2026CEL-SCI Closes $2.5 Million Stock Offering Benzinga · June 16, 2026CEL-SCI Announces Dual-Track Strategy To Bring Multikine To Patients With Head And Neck Cancer Through Parallel Regulatory Pathways In The U.S. And Saudi Arabia Benzinga · June 12, 2026CEL‑SCI To Sign Saudi Amarox Deal At BIO International Convention 2026, Advancing Multikine Commercialization In Saudi Arabia Mt Newswire · May 18, 2026Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing Benzinga · May 15, 2026CEL-SCI Q2 EPS $(0.67) Down From $(0.08) YoY Benzinga · May 11, 2026CEL-SCI Signs Strategic Partnership, Distribution, And Revenue Sharing Agreement With Amarox For Regulatory Affairs, Marketing And Potential Commercialization Of Multikine In Treatment Of Head And Neck Cancer In Saudi Arabia